From JPMA Toward Strengthening Japan's Drug Discovery Capability
Since the 2000s, the trend in drug development has shifted from small molecules to a variety of modalities, including biotechnology. The JPMA has made it a top priority to "strengthen Japan's drug discovery capabilities" in order to drive the continued rapid flow of innovation toward practical application. The establishment of a "drug discovery eco-system" is urgently needed. The "Expert Panel on Comprehensive Measures to Achieve a Rapid and Stable Supply of Pharmaceuticals" organized by the Ministry of Health, Labour and Welfare (MHLW) has also identified support for the creation of new modalities and the establishment of a drug discovery ecosystem as measures to strengthen drug discovery capabilities, and momentum is building for a national effort. I believe that the drug discovery ecosystem fits well with the Japanese national character, which values harmony, friendship, and constant effort.
On the other hand, for the drug discovery ecosystem to function, in addition to a mechanism to connect all players, an environment that attracts technology, people, and capital from around the world is necessary. For this to happen, Japan must be an attractive market where the value of innovation is appropriately evaluated. The price of pharmaceuticals is an official price and cannot be set by the will of the company alone, but we will work to gain the understanding of all concerned parties and the public in order to set an appropriate price for innovative new drugs. We will also contribute to the revitalization of the drug discovery ecosystem by actively injecting qualified human resources from Japan and abroad, including those from the pharmaceutical industry.
Japan Pharmaceutical Manufacturers Association
Chairman Hiroaki Ueno
We recognize that the time has come for us to take over the baton from our predecessors and bring it to fruition. We believe that the two elements of "strengthening Japan's drug discovery capabilities" and "appropriate evaluation of innovation" will work in tandem and form a virtuous cycle, making Japan a country where innovation is vibrant and innovative drugs can be continuously produced. We are committed to working together as a united industry, with each company working diligently to improve its own skills and capabilities.
(From a contribution to the newspaper)
Japan Pharmaceutical Manufacturers Association (JPMA)
Japan Pharmaceutical Manufacturers Association (JPMA)
JPMA is a voluntary association of R&D-oriented pharmaceutical companies, established in 1968, with the motto of "realization of patient-participatory medicine," and has contributed to global healthcare through the development of innovative new drugs for ethical use.
JPMA is engaged in a multifaceted program of activities to solve various problems common to the pharmaceutical industry, to deepen understanding of pharmaceuticals, and to promote international collaboration. In addition, we are committed to the sound development of the pharmaceutical industry, particularly by strengthening our policy formulation and advocacy activities, addressing internationalization, and reinforcing our public relations system.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association